USP4 Targets TAK1 to Downregulate TNFα-induced NF-κB Activation

Overview

Journal Cell Death Differ

Specialty Cell Biology

Date 2011 Feb 19

PMID 21331078

Citations 85

Authors

Y-H Fan

Y Yu

R-F Mao

X-J Tan

G-F Xu

H Zhang

X-B Lu

S-B Fu

J Yang

Affiliations

Soon will be listed here.

Abstract

Lys63-linked polyubiquitination of transforming growth factor-β-activated kinase 1 (TAK1) has an important role in tumor necrosis factor-α (TNFα)-induced NF-κB activation. Using a functional genomic approach, we have identified ubiquitin-specific peptidase 4 (USP4) as a deubiquitinase for TAK1. USP4 deubiquitinates TAK1 in vitro and in vivo. TNFα induces association of USP4 with TAK1 to deubiquitinate TAK1 and downregulate TAK1-mediated NF-κB activation. Overexpression of USP4 wild type, but not deuibiquitinase-deficient C311A mutant, inhibits both TNFα- and TAK1/TAB1 co-overexpression-induced TAK1 polyubiquitination and NF-κB activation. Notably, knockdown of USP4 in HeLa cells enhances TNFα-induced TAK1 polyubiquitination, IκB kinase phosphorylation, IκBα phosphorylation and ubiquitination, as well as NF-κB-dependent gene expression. Moreover, USP4 negatively regulates IL-1β-, LPS- and TGFβ-induced NF-κB activation. Together, our results demonstrate that USP4 serves as a critical control to downregulate TNFα-induced NF-κB activation through deubiquitinating TAK1.

Citing Articles

Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects.

Bakkar M, Khalil S, Bhayekar K, Kushwaha N, Samarbakhsh A, Dorandish S Biomolecules. 2025; 15(2).

PMID: 40001543 PMC: 11853158. DOI: 10.3390/biom15020240.

Deubiquitinases as novel therapeutic targets for diseases.

Xian Y, Ye J, Tang Y, Zhang N, Peng C, Huang W MedComm (2020). 2024; 5(12):e70036.

PMID: 39678489 PMC: 11645450. DOI: 10.1002/mco2.70036.

PBLD enhances antiviral innate immunity by promoting the p53-USP4-MAVS signaling axis.

Chu F, Hou P, Zhu H, Gao Y, Wang X, He W Proc Natl Acad Sci U S A. 2024; 121(49):e2401174121.

PMID: 39589880 PMC: 11626120. DOI: 10.1073/pnas.2401174121.

Literature review: nuclear factor kappa B (NF-κB) regulation in human cancers mediated by ubiquitin-specific proteases (USPs).

Shen K, Zhang Q Ann Transl Med. 2024; 12(5):90.

PMID: 39507445 PMC: 11534757. DOI: 10.21037/atm-24-32.

USP4 regulates ribosome biogenesis and protein synthesis for hematopoietic stem cell regeneration and leukemia progression.

Liu B, Zhang X, Zhou Y, Liu H, Wang Z, Fu Y Leukemia. 2024; 38(11):2466-2478.

PMID: 39266638 DOI: 10.1038/s41375-024-02338-z.

References

Shim J, Xiao C, Paschal A, Bailey S, Rao P, Hayden M . TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 2005; 19(22):2668-81. PMC: 1283960. DOI: 10.1101/gad.1360605. View

Beg A, Baldwin Jr A . The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes Dev. 1993; 7(11):2064-70. DOI: 10.1101/gad.7.11.2064. View

Jiang Z, Ninomiya-Tsuji J, Qian Y, Matsumoto K, Li X . Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol. Mol Cell Biol. 2002; 22(20):7158-67. PMC: 139807. DOI: 10.1128/MCB.22.20.7158-7167.2002. View

Zhang J, Stirling B, Temmerman S, Ma C, Fuss I, Derry J . Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest. 2006; 116(11):3042-9. PMC: 1616194. DOI: 10.1172/JCI28746. View

Delhase M, Hayakawa M, Chen Y, Karin M . Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science. 1999; 284(5412):309-13. DOI: 10.1126/science.284.5412.309. View

Ea C, Deng L, Xia Z, Pineda G, Chen Z . Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell. 2006; 22(2):245-57. DOI: 10.1016/j.molcel.2006.03.026. View

Mao R, Fan Y, Mou Y, Zhang H, Fu S, Yang J . TAK1 lysine 158 is required for TGF-β-induced TRAF6-mediated Smad-independent IKK/NF-κB and JNK/AP-1 activation. Cell Signal. 2010; 23(1):222-7. PMC: 2956842. DOI: 10.1016/j.cellsig.2010.09.006. View

Baud V, Karin M . Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001; 11(9):372-7. DOI: 10.1016/s0962-8924(01)02064-5. View

Fan Y, Yu Y, Mao R, Zhang H, Yang J . TAK1 Lys-158 but not Lys-209 is required for IL-1β-induced Lys63-linked TAK1 polyubiquitination and IKK/NF-κB activation. Cell Signal. 2010; 23(4):660-5. PMC: 3035988. DOI: 10.1016/j.cellsig.2010.11.017. View

10.

Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K . The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature. 1999; 398(6724):252-6. DOI: 10.1038/18465. View

11.

Hayden M, Ghosh S . Signaling to NF-kappaB. Genes Dev. 2004; 18(18):2195-224. DOI: 10.1101/gad.1228704. View

12.

Alvarez S, Harikumar K, Hait N, Allegood J, Strub G, Kim E . Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010; 465(7301):1084-8. PMC: 2946785. DOI: 10.1038/nature09128. View

13.

Fan Y, Yu Y, Shi Y, Sun W, Xie M, Ge N . Lysine 63-linked polyubiquitination of TAK1 at lysine 158 is required for tumor necrosis factor alpha- and interleukin-1beta-induced IKK/NF-kappaB and JNK/AP-1 activation. J Biol Chem. 2009; 285(8):5347-60. PMC: 2820763. DOI: 10.1074/jbc.M109.076976. View

14.

Reiley W, Zhang M, Jin W, Losiewicz M, Donohue K, Norbury C . Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol. 2006; 7(4):411-7. DOI: 10.1038/ni1315. View

15.

Takaesu G, Kishida S, Hiyama A, Yamaguchi K, Shibuya H, Irie K . TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell. 2000; 5(4):649-58. DOI: 10.1016/s1097-2765(00)80244-0. View

16.

Li H, Kobayashi M, Blonska M, You Y, Lin X . Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation. J Biol Chem. 2006; 281(19):13636-13643. DOI: 10.1074/jbc.M600620200. View

17.

Yin Q, Lamothe B, Darnay B, Wu H . Structural basis for the lack of E2 interaction in the RING domain of TRAF2. Biochemistry. 2009; 48(44):10558-67. PMC: 2830148. DOI: 10.1021/bi901462e. View

18.

Mahoney D, Cheung H, Mrad R, Plenchette S, Simard C, Enwere E . Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci U S A. 2008; 105(33):11778-83. PMC: 2575330. DOI: 10.1073/pnas.0711122105. View

19.

Li S, Wang L, Dorf M . PKC phosphorylation of TRAF2 mediates IKKalpha/beta recruitment and K63-linked polyubiquitination. Mol Cell. 2009; 33(1):30-42. PMC: 2643372. DOI: 10.1016/j.molcel.2008.11.023. View

20.

Chen Z . Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol. 2005; 7(8):758-65. PMC: 1551980. DOI: 10.1038/ncb0805-758. View